Market Overview

UPDATE: Deutsche Bank Upgrades Tenet Healthcare to Buy on Compelling Outlook

Share:
Related THC
Keep An Eye On This New Activist Hedge Fund Managed By Former JPMorgan Executives
The Top 20 Wall Street Analysts Of 2015

Deutsche Bank raised its rating on Tenet Healthcare (NYSE: THC) from Hold to Buy and increased its price target from $31 to $38.

Deutsche Bank noted, "Our upgrade is underpinned by: (1) clear signs of improving business mix and margins due especially to gains in outpatient, (2) tangible momentum in Conifer, and (3) a more sustainable FCF profile going forward. We also continue to highlight the upside risks due to PPACA, and note our 2014 EPS of $3.85 is 17% above consensus. Due to a more favorable outlook, we believe THC should be positioned to garner an in-line (~6x) fwd EV/EBITDA multiple."

Tenet Healthcare closed at $30.63 on Thursday.

Latest Ratings for THC

DateFirmActionFromTo
Jan 2016Mizuho SecuritiesUpgradesNeutralBuy
Jan 2016Wells FargoDowngradesOutperformMarket Perform
Dec 2015Credit SuisseInitiates Coverage onNeutral

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (THC)

Get Benzinga's Newsletters